Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
IPO Year:
Exchange: NYSE
Website: pfizer.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2025 | $24.00 | Neutral | Cantor Fitzgerald |
| 12/10/2024 | $29.00 | Neutral | BofA Securities |
| 11/15/2024 | $25.00 | Underperform | Wolfe Research |
| 10/25/2024 | $30.00 | Neutral | Citigroup |
| 10/17/2024 | $32.00 | Mkt Perform | Bernstein |
| 8/7/2024 | Neutral → Outperform | Daiwa Securities | |
| 3/22/2024 | Buy → Hold | Argus | |
| 2/23/2024 | $36.00 | Buy | Guggenheim |
| 1/4/2024 | $32.00 | Outperform → Market Perform | TD Cowen |
| 10/20/2023 | $36.00 → $34.00 | Neutral | UBS |
CERT - PFIZER INC (0000078003) (Filer)
8-K - PFIZER INC (0000078003) (Filer)
FWP - PFIZER INC (0000078003) (Subject)
13F-HR - PFIZER INC (0000078003) (Filer)
10-Q - PFIZER INC (0000078003) (Filer)
8-K - PFIZER INC (0000078003) (Filer)
8-K - PFIZER INC (0000078003) (Filer)
DEFA14A - PFIZER INC (0000078003) (Filer)
DEFA14A - PFIZER INC (0000078003) (Filer)
DEFA14A - PFIZER INC (0000078003) (Filer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with placebo plus ADTXTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive prostate cancerData continue to show wide-ranging effect of treatment with XTANDI (enzalutamide) plus ADT across various patient subgroups, notably those with high-vo
Pfizer Inc. (NYSE:PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. SSGJ-707 has shown initial efficacy and safety data in a promising class of cancer medicines. 3SBio plans to initiate the first Phase 3 study in China in 2025. Under the terms of the agreement, 3SBio and its subsidiaries Shenyang Sunshine Pharmaceutical C
Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment Made Significant Progress Strengthening the R&D Organization On Track to Exceed Net Cost Savings Targets Pfizer Inc. (NYSE:PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved productivity. With the underlying strength of our business, we believe we can be agile in navigating an uncertain and volatile external environment." Dav
Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) regimen compared to SOC alone Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in more than 30 years Results have been shared with global health authorities to support potential regulatory filings Pfizer Inc. (NYSE:PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an inves
Multi-year global collaboration will utilize Guardant liquid biopsy portfolio in research and clinical applications and evaluate utility of ctDNA for monitoring therapy response Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE), to support the development and commercialization of Pfizer's oncology portfolio using the Guardant Infinity™ smart liquid biopsy platform. Under the multi-year collaboration agreement, Guardant and Pfizer aim to: Utilize Guardant's portfolio of liquid biopsy tests in Pfizer's global clinical studies Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) le
Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company's common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, develo
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74 Pfizer Inc. (NYSE:PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased risk
Pfizer Inc. (NYSE:PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management. Pfizer's dose-optimization studies of once-daily formulations of danuglipron (NCT06567327 and NCT06568731) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron. While the overall frequency of liver enzyme elevations across the over 1,400 participant safety database of danuglipron is in-line with appro
Pfizer Inc. (NYSE:PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24, 2025. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who participate will be afforded comparable rights and opportunities to participate as they would at an in-person meeting. Beginning today, shareholders can find additional information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2025. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control numbe
ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the company's bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age. This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now offers in the EU the broadest RSV vaccine indication, which includes: Active immunization of individuals 18 ye
Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00
BofA Securities resumed coverage of Pfizer with a rating of Neutral and set a new price target of $29.00
Wolfe Research initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00
Citigroup resumed coverage of Pfizer with a rating of Neutral and set a new price target of $30.00
Bernstein initiated coverage of Pfizer with a rating of Mkt Perform and set a new price target of $32.00
Daiwa Securities upgraded Pfizer from Neutral to Outperform
Argus downgraded Pfizer from Buy to Hold
Guggenheim initiated coverage of Pfizer with a rating of Buy and set a new price target of $36.00
TD Cowen downgraded Pfizer from Outperform to Market Perform and set a new price target of $32.00
UBS resumed coverage of Pfizer with a rating of Neutral and set a new price target of $34.00 from $36.00 previously
For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter
Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:
For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro
Submission status for PFIZER INC's drug ELREXFIO (SUPPL-2) with active ingredient ELRANATAMAB has changed to 'Approval' on 09/10/2024. Application Category: BLA, Application Number: 761345, Application Classification:
For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons
For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of
For Immediate Release: August 22, 2024 Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating var
Submission status for PFIZER INC's drug NICOTROL (SUPPL-12) with active ingredient NICOTINE has changed to 'Approval' on 05/23/2024. Application Category: NDA, Application Number: 020385, Application Classification: Labeling
Submission status for PFIZER INC's drug TALZENNA (ORIG-1) with active ingredient TALAZOPARIB has changed to 'Approval' on 03/07/2024. Application Category: NDA, Application Number: 217439, Application Classification: Type 5 - New Formulation or New Manufacturer
Submission status for PFIZER INC's drug IXIFI (SUPPL-9) with active ingredient INFLIXIMAB-QBTX has changed to 'Approval' on 12/26/2023. Application Category: BLA, Application Number: 761072, Application Classification:
SC 13G/A - PFIZER INC (0000078003) (Subject)
SC 13D - PFIZER INC (0000078003) (Filed by)
SC 13G/A - PFIZER INC (0000078003) (Subject)
SC 13G/A - PFIZER INC (0000078003) (Subject)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment Made Significant Progress Strengthening the R&D Organization On Track to Exceed Net Cost Savings Targets Pfizer Inc. (NYSE:PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved productivity. With the underlying strength of our business, we believe we can be agile in navigating an uncertain and volatile external environment." Dav
Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company's common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, develo
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the conference
Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 10:30 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfize
Full-Year 2024 Revenues of $63.6 Billion, Reflecting 7% Year-over-Year Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 12% Operationally Full-Year 2024 Reported(2) Diluted EPS of $1.41 and Adjusted(3) Diluted EPS of $3.11 Fourth-Quarter 2024 Revenues of $17.8 Billion, Reflecting 21% Year-over-Year Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 11% Operationally Fourth-Quarter 2024 Reported(2) Diluted EPS of $0.07 and Adjusted(3) Diluted EPS of $0.63 On Track to Deliver Overall Net Cost Savings of Approximately $4.5 Billion by End of 2025 from Ongoing Cost Realignment Program(4) Reaff
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Fourth Quarter and Full Year 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also liste
Full-Year 2025 Revenue Guidance(1) Range of $61.0 to $64.0 Billion Full-Year 2025 Adjusted(2) Diluted EPS Guidance Range of $2.80 to $3.00 Expect Full-Year 2025 Adjusted(2) Diluted EPS Operational(3) Growth of 10% to 18% from the Midpoint of 2024 Guidance After Adjusting for 2024 Non-Recurring Items(4) Achieved Goal of $4.0 Billion in Net Cost Savings Through 2024 and Anticipate an Additional $500 Million in Savings in 2025 from Ongoing Cost Realignment Program First Phase of Manufacturing Optimization Program On Track to Deliver Initial Net Cost Savings in the Latter Part of 2025, Toward Goal of Improving Gross Margin Performance Pfizer Inc. (NYSE:PFE) today provided its fu
Board of Directors approves increase in quarterly cash dividend to $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer. "Our decision to increase our quarterly dividend underscores our strong financial performance, disciplined execution and our commitment to returning value to our shareholders," said Dr. Albert Bourla, Pfiz
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:30 a.m. EST on Tuesday, December 17, 2024. The purpose of the call is to provide Pfizer's full-year 2025 financial guidance. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the conference call by dialing either 800-456-4352 in the United States and Canada or 785-424-1086 outside of the United Stat
Third-Quarter Performance Driven by Focused Commercial Execution and Robust Double-Digit Revenue Growth Across Product Portfolio Raises Full-Year 2024 Revenue Guidance(1) to a Range of $61.0 to $64.0 Billion and Raises Adjusted(2) Diluted EPS Guidance to a Range of $2.75 to $2.95 Third-Quarter 2024 Revenues of $17.7 Billion, Representing 32% Year-over-Year Operational Growth Excluding Contributions from Paxlovid and Comirnaty(3), Revenues Grew 14% Operationally Third-Quarter 2024 Reported(4) Diluted EPS of $0.78 and Adjusted(2) Diluted EPS of $1.06 On Track to Deliver Net Cost Savings of At Least $5.5 Billion from Previously Announced Cost Reduction Initiatives At Least $4 B
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid
Industry veteran in clinical development of oncology therapeutics, Dr. Jens Wurthner, PhD, joins as Chief Medical Officer Lead development candidate, FORX-428, a PARG inhibitor for solid tumors, maintains progress toward IND submission by mid-2025 FoRx Therapeutics AG, a Swiss-based company committed to discovering and developing innovative drugs targeting cancer-relevant DDR (DNA Damage Response) pathways, today announced that it has appointed Jens Würthner, MD PhD, as Chief Medical Officer. He is further strengthening FoRx Therapeutics' existing management team with CEO Tarig Bashir, CSO Frank Zenke, and Head of Chemistry Ulrich Lücking. Jens Würthner has 20+ years of clinical devel
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov
Stuart Therapeutics adds recognized leaders in ophthalmology therapeutics development, commercialization. STUART, Fla., Dec. 22, 2024 /PRNewswire/ -- Stuart Therapeutics announced today the appointment of Tracy Valorie and Jason Werner to the company's Board of Directors, bringing the total number of Board members to five. These new Directors will hold the positions previously held by Robert O. Baratta, MD, who passed away suddenly in the third quarter of this year, and retired US Representative Diane Black, RN, who recently resigned her position on the company's Board. Tracy
Chris Boshoff to lead all Research and Development functions including Oncology Oncology Unit end-to-end structure to remain intact, reporting to Boshoff Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer Pfizer Inc. (NYSE:PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer wa
Pfizer Inc. (NYSE:PFE) today announced the election of Mortimer ("Tim") J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. Buckley, age 55, was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer's Board. Following the appointment of Mr. Buckley, the Board will comprise 14 directors, 13 of whom are independent. Mr. Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024. Previously he was Vanguard's Chief Investment Officer, overseeing the company's internally managed stock, bond and money market portf
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent director to its Board of Directors. Dr. Dolsten is an accomplished industry executive with extensive global pharmaceutical management experience. "As an industry-leading pharmaceutical executive, I am very pleased to welcome Mikael to our Board of Directors," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. "His research and development experience will help advance our leading scientific capabilities and
HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager. Mr. Barnum will oversee the process management, quality, and operations of ALTIVIA's Specialty and Oxide Chemicals' units. Mr. Hale will lead the development and management of ALTIVIA's Corporate Engineering Department. "We look forward to welcoming both Scott and Dean as ALTIVIA furthers its investment in growth, sustainability, and world-class operating performance," said Michael Jusbasche, ALTIVIA's Chief
Pfizer Inc. (NYSE:PFE) invites investors and the general public to access a live video webcast of its Oncology Innovation Day on Thursday, February 29, 2024, from 1:00 p.m. EST to 5:30 p.m. EST, with an approximately 20-minute break at the midpoint. During the event, Pfizer Oncology leadership will provide details on the new combined Pfizer Oncology Division, including its strategic approach, robust portfolio, industry-leading R&D capabilities and potential for growth through 2030 and beyond. To access the live webcast and presentation slides, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/invest
Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, to be effective August 1, 2023 Current President and Chief Executive Officer, Ankit Mahadevia, M.D to become Chairman of the Board of Directors CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Satyavrat "Sath" Shukla, Spero's current Chief Financial Officer and Treas